Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe

Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00211-20. doi: 10.1128/AAC.00211-20. Print 2020 Apr 21.

Abstract

Nine hundred Haemophilus influenzae clinical isolates from 83 U.S. and European medical centers were tested for susceptibility by reference broth microdilution methods against ceftolozane-tazobactam and comparators. Results were stratified by β-lactamase production and infection type. Overall, ceftolozane-tazobactam MIC50/90 values were 0.12/0.25 mg/liter, and 99.0% of isolates were inhibited at the susceptible breakpoint of ≤0.5 mg/liter; the highest MIC value was only 2 mg/liter. Our results support using ceftolozane-tazobactam to treat H. influenzae infections.

Keywords: Haemophilus influenzae; ceftolozane-tazobactam; cephalosporin; susceptibility testing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Cephalosporins / therapeutic use*
  • Drug Resistance, Multiple, Bacterial / genetics
  • Europe
  • Haemophilus Infections / drug therapy*
  • Haemophilus influenzae / drug effects*
  • Haemophilus influenzae / genetics
  • Haemophilus influenzae / isolation & purification
  • Humans
  • Microbial Sensitivity Tests
  • Tazobactam / therapeutic use*
  • United States

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • ceftolozane, tazobactam drug combination
  • Tazobactam